Literature DB >> 32743153

Identification and validation of the mode of action of the chalcone anti-mycobacterial compounds.

B Anagani1, J Singh1, J P Bassin1, G S Besra2, C Benham1, T R K Reddy3, J A G Cox4, M Goyal1.   

Abstract

OBJECTIVES: The search for new TB drugs has become one of the great challenges for modern medicinal chemistry. An improvement in the outcomes of TB chemotherapy can be achieved by the development of new, shorter, cheap, safe and effective anti-TB regimens.
METHODS: Chalcones (1a-1o) were synthesized and evaluated for their antimycobacterial activity against Mycobacterium bovis BCG using growth inhibition assays. Compound 1a was selected as a 'hit' compound. The mode of action of compound 1a, was identified by mycolic acid methyl esters (MAMEs) and fatty acid methyl esters (FAMEs) analysis using thin layer chromatography. Dose dependent experiments were conducted by over-expressing components of FAS-II in M. bovis BCG to confirm the target. Ligand binding using intrinsic tryptophan assay and molecular docking were used to further validate the target.
RESULTS: MAMEs and FAMEs analysis showed dose-dependent reduction of MAMEs with the overall abundance of FAMEs suggesting that compound 1a targets mycolic acid biosynthesis. Direct binding of 1a to InhA was observed using an intrinsic tryptophan fluorescence binding assay, and a 2-fold IC50 shift was observed with an InhA overexpressing strain confirming InhA as the cellular target.
CONCLUSION: The chalcone 1a exhibits potent antimycobacterial activity, displays a good safety profile and is a direct inhibitor of InhA, a key component in mycolic acid synthesis, validating this series for further anti-TB drug development.
© 2020 Published by Elsevier B.V.

Entities:  

Keywords:  Chalcones; Docking; InhA; MIC; Mycolic Acids; Tuberculosis

Year:  2020        PMID: 32743153      PMCID: PMC7388970          DOI: 10.1016/j.tcsw.2020.100041

Source DB:  PubMed          Journal:  Cell Surf        ISSN: 2468-2330


  34 in total

Review 1.  Drugs for bad bugs: confronting the challenges of antibacterial discovery.

Authors:  David J Payne; Michael N Gwynn; David J Holmes; David L Pompliano
Journal:  Nat Rev Drug Discov       Date:  2006-12-08       Impact factor: 84.694

Review 2.  Identification and validation of novel drug targets in Mycobacterium tuberculosis.

Authors:  Vinayak Singh; Valerie Mizrahi
Journal:  Drug Discov Today       Date:  2016-09-17       Impact factor: 7.851

3.  New Approaches to Prevent Healthcare-Associated Infection.

Authors:  Philippe Brouqui; Sophia Boudjema; Alberto Soto Aladro; Eric Chabrière; Olga Florea; Hoa Nguyen; Jean Charles Dufour
Journal:  Clin Infect Dis       Date:  2017-08-15       Impact factor: 9.079

4.  In vitro activity of a novel antimycobacterial compound, N-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis.

Authors:  N M Parrish; T Houston; P B Jones; C Townsend; J D Dick
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Triclosan inhibition of mycobacterial InhA in Saccharomyces cerevisiae: yeast mitochondria as a novel platform for in vivo antimycolate assays.

Authors:  A Gurvitz
Journal:  Lett Appl Microbiol       Date:  2010-01-27       Impact factor: 2.858

6.  The missing piece of the type II fatty acid synthase system from Mycobacterium tuberculosis.

Authors:  Emmanuelle Sacco; Adrian Suarez Covarrubias; Helen M O'Hare; Paul Carroll; Nathalie Eynard; T Alwyn Jones; Tanya Parish; Mamadou Daffé; Kristina Bäckbro; Annaïk Quémard
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-05       Impact factor: 11.205

7.  Chalcones and flavonoids as anti-tuberculosis agents.

Authors:  Yuh-Meei Lin; Yasheen Zhou; Michael T Flavin; Li-Ming Zhou; Weiguo Nie; Fa-Ching Chen
Journal:  Bioorg Med Chem       Date:  2002-08       Impact factor: 3.641

8.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.

Authors:  A Banerjee; E Dubnau; A Quemard; V Balasubramanian; K S Um; T Wilson; D Collins; G de Lisle; W R Jacobs
Journal:  Science       Date:  1994-01-14       Impact factor: 47.728

9.  World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.

Authors:  Dennis Falzon; Holger J Schünemann; Elizabeth Harausz; Licé González-Angulo; Christian Lienhardt; Ernesto Jaramillo; Karin Weyer
Journal:  Eur Respir J       Date:  2017-03-22       Impact factor: 16.671

Review 10.  Mycobacterium tuberculosis Molecular Determinants of Infection, Survival Strategies, and Vulnerable Targets.

Authors:  Davide M Ferraris; Riccardo Miggiano; Franca Rossi; Menico Rizzi
Journal:  Pathogens       Date:  2018-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.